LexaGene Completes First Stage of U.S. ARMY DEVCOM Agreement

BEVERLY, Mass., Oct. 29, 2021 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., ( OTCQB: LXXGF; TSX-V: LXG ) (“LexaGene” or the “Company”), a molecular diagnostics company that has commercialized an instrument

Related Keywords

Maryland ,United States ,Gail Winslow ,Manoj Nair ,Lexagene Miqlab ,Jack Regan ,Development Agreement ,Applications Assay Development At Lexagene ,Lexagene Holdings Inc ,Chemical Biological Center At Aberdeen Proving Grounds ,Venture Exchange Inc ,Us Army ,Capabilities Development Command ,Venture Exchange ,Regulation Services Provider ,Gene Holdings ,Cooperative Research ,Combat Capabilities Development Command ,Biological Center ,Aberdeen Proving Grounds ,United States Postal ,Director Applications ,Assay Development ,Jack Regan Chief Executive Officer ,Lexagene Holdings ,Media Contact ,Gail Winslow Director ,Corporate Marketing ,Sharon Choe Vice President Lavoiehealthscience ,Money ,Ational ,